Ardelyx Inc (ARDX)vsargenx NV ADR (ARGX)
ARDX
Ardelyx Inc
$3.58
-1.10%
HEALTHCARE · Cap: $975.95M
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 1079% more annual revenue ($5.32B vs $450.89M). ARGX leads profitability with a 32.3% profit margin vs -12.3%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARDX
Avoid31
out of 100
Grade: F
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARDX.
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 23.8% year-over-year
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARDX
The strongest argument for ARDX centers on Revenue Growth. Revenue growth of 23.8% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bear Case : ARDX
The primary concerns for ARDX are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.72 is elevated, increasing financial risk.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ARDX carries more volatility with a beta of 0.69 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 31/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ardelyx Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
Visit Website →argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?